US2017189489A1PendingUtilityA1
Cardiac muscle function and manipulation
Assignee: ZENSUN (SHANGHAI) SCIENCE & TECH CO LTDPriority: Dec 21, 1998Filed: Aug 12, 2016Published: Jul 6, 2017
Est. expiryDec 21, 2018(expired)· nominal 20-yr term from priority
Inventors:Mingdong Zhou
G01N 2800/32A61K 38/1883C12N 5/0657G01N 33/6887G01N 33/74A61P 9/00G01N 2333/4756G01N 2800/325
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.
Claims
exact text as granted — not AI-modified1 . A method for treating heart failure in a mammal in need thereof, comprising administering an effective amount of a neuregulin or a neuregulin analog to the mammal, wherein the neuregulin or neuregulin analog is a neuregulin isoform or a polypeptide comprising a neuregulin EGF domain.
Join the waitlist — get patent alerts
Track US2017189489A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.